Fig. 2: Selection of candidate protein replacement therapeutics from the unused intermediates proteome for proof-of-concept studies.

a Heatmap reporting prioritized proteins from the proteome of unused intermediates. For each protein the associated disease is indicated (“*”= non-rare diseases) and the Gene-Disease Association (GDA) from 0.7 (in light blue) to 1 (in navy blue). The higher is the score, the higher is the gene-disease association. b Plasma proteins present in unused fractionation intermediates for which evidence of preclinical efficacy is available. Applicable prevalence data are indicated^15,77,78. Relevant references for Preclinical proof of concept (PoC) for replacement therapy for Haptoglobin^40,41 (HP), ceruloplasmin²⁰ (CP), Transferrin⁴² (TF) and Hemopexin²³ (HPX) are indicated.